Suppr超能文献

房颤相关性缺血性卒中患者,既往抗凝治疗者,复发卒中风险更高。

Atrial Fibrillation-Associated Ischemic Stroke Patients With Prior Anticoagulation Have Higher Risk for Recurrent Stroke.

机构信息

From the Division of Stroke Care Unit (K. Tanaka), National Cerebral and Cardiovascular Center, Suita, Japan.

Department of Neurology, Keio University School of Medicine, Tokyo, Japan (K. Tanaka, J.N., N.S., K. Toyoda).

出版信息

Stroke. 2020 Apr;51(4):1150-1157. doi: 10.1161/STROKEAHA.119.027275. Epub 2020 Feb 26.

Abstract

Background and Purpose- Ischemic stroke associated with nonvalvular atrial fibrillation (NVAF) despite prior anticoagulation may indicate underlying problems that nullify the stroke-preventing effects of oral anticoagulants. We aimed to evaluate the risk for recurrent stroke in patients with NVAF with prior anticoagulation, compared with that in patients without prior anticoagulation. Methods- This study comprised pooled individual patient data on NVAF-associated acute ischemic stroke or transient ischemic attack from 2011 to 2014 arising from the Clinical Research Collaboration for Stroke in Korea (15 South Korean stroke centers) and the Stroke Acute Management With Urgent Risk-Factor Assessment and Improvement-NVAF registry (18 Japanese stroke centers). Data on 4841 eligible patients from the Clinical Research Collaboration for Stroke in Korea registry were pooled with data on all patients (n=1192) in the Stroke Acute Management with Urgent Risk-factor Assessment and Improvement-NVAF registry. The primary outcome was recurrent ischemic stroke. The secondary outcomes were hemorrhagic stroke and all-cause death. Outcome events were captured up to 1 year after the index event. Results- Among the 6033 patients in the full cohort, 5645 patients were analyzed, of whom 1129 patients (20.0%) had received prior anticoagulation. Median age was 75 years (interquartile range, 69-81 years), and 2649 patients (46.9%) were women. Follow-up data of 4617 patient-years (median follow-up 365 days, interquartile range 335-365 days) were available. The cumulative incidence of recurrent ischemic stroke in patients with prior anticoagulation was 5.3% (60/1129), compared with the 2.9% (130/4516) incidence in patients without prior anticoagulation. The risk for recurrent ischemic stroke was higher in patients with prior anticoagulation than in those without (multivariable Cox shared-frailty model, hazard ratio 1.50 [95% CI, 1.02-2.21]). No significant differences in the risks for hemorrhagic stroke and mortality were seen between the 2 groups. Conclusions- The risk for recurrent ischemic stroke may be higher in NVAF-associated stroke patients with prior anticoagulation than in those without prior anticoagulation. Registration- URL: https://www.clinicaltrials.gov; Unique identifier: NCT01581502.

摘要

背景与目的-尽管进行了抗凝治疗,但与非瓣膜性心房颤动(NVAF)相关的缺血性卒中可能表明存在一些问题,这些问题抵消了口服抗凝剂的卒中预防作用。我们旨在评估 NVAF 患者在接受抗凝治疗之前与未接受抗凝治疗的患者相比,复发性卒中的风险。方法-本研究纳入了 2011 年至 2014 年来自韩国临床研究协作卒中(15 家韩国卒中中心)和卒中急性管理及紧急风险因素评估和改善-NVAF 登记(18 家日本卒中中心)的 NVAF 相关急性缺血性卒中和短暂性脑缺血发作的个体患者数据。来自韩国临床研究协作卒中登记的 4841 例合格患者的数据与卒中急性管理及紧急风险因素评估和改善-NVAF 登记中所有患者(n=1192)的数据进行了汇总。主要结局是复发性缺血性卒中。次要结局是出血性卒中和全因死亡。结局事件在指数事件后 1 年内进行了监测。结果-在全队列的 6033 例患者中,对 5645 例患者进行了分析,其中 1129 例(20.0%)患者接受了抗凝治疗。中位年龄为 75 岁(四分位距,69-81 岁),2649 例(46.9%)为女性。有 4617 患者年的随访数据(中位随访 365 天,四分位距 335-365 天)。在接受抗凝治疗的患者中,复发性缺血性卒中的累积发生率为 5.3%(60/1129),而未接受抗凝治疗的患者为 2.9%(130/4516)。接受抗凝治疗的患者发生复发性缺血性卒中的风险高于未接受抗凝治疗的患者(多变量共享脆弱性 Cox 模型,风险比 1.50[95%CI,1.02-2.21])。两组间出血性卒中和死亡率的风险无显著差异。结论-与未接受抗凝治疗的 NVAF 相关卒中患者相比,接受抗凝治疗的 NVAF 相关卒中患者复发性缺血性卒中的风险可能更高。注册-网址:https://www.clinicaltrials.gov;唯一标识符:NCT01581502。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验